Peak Pharmaceuticals Updates Research and Commercial Activities for Q1
Company Research Lab Nears Completion, Canna-Pet™ Prepares for Amazon, and 1st Ever CBD for Animals Public Survey a Success
(firmenpresse) - BOULDER, CO -- (Marketwired) -- 03/03/15 -- (OTCQB: PKPH) ("Peak Pharma" or the "Company"), a growth stage company aiming to become a leader in the research, development, sales and marketing of safe, hemp-based supplements for both humans and animals has enjoyed an active beginning to the year and wishes to provide a Q1 2015 update of ongoing research and commercial activities.
The Company recently acquired additional scientific equipment for its laboratory facilities at the BioScience Park Center located on the Anschutz Medical Campus at the University of Colorado, Denver. Ongoing research activities aim to leverage the Company''s 2014 hemp crop into product prototypes for testing, production, and ultimately groundbreaking first-to-market hemp-based supplement products. The company plans to develop anti-inflammatory products aimed at the human health market, as well as additional products for the veterinary market.
In the animal health segment of the business, the company is increasing production capacity for its Canna-Pet™ line of products, with the goal of growing retail sales through veterinary clinics and retail stores, in addition to its current online ecommerce portal (). Current efforts are underway to market and sell Canna-Pet™ through the Amazon network and additional details will be made available once the product is launched.
In related news, at the beginning of February, the Canna-Pet™ website was used to launch what is believed to be the first ever public survey regarding the actual customer application and use of CBD-rich, hemp based animal supplements. The Company is very pleased to report that the participation and response to the survey significantly exceeded expectations and as such, the data sample should prove instrumental in the development and marketing of a wide variety of next generation products.
Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang notes, "It''s been a very busy start to 2015 and we are thrilled by the upsurge in activity. Our company is growing, and with current research and development activities aimed at launching our first human health product later this year, we expect to continue increasing revenues from product sales. Along this line, expansion into new channel markets for our animal products is an important step towards targeting a broader segment of consumers. I''d also like to thank everyone who participated in our animal health survey. This survey data is critically important to our R&D activities and we hope to pay you all back with even better products in future."
Additional details of the Company''s business, finances, appointments and agreements can be found as part of the Company''s continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at . For more information please visit .
(OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of hemp and cannabinoid based supplements. For more information visit and follow us on , and .
Canna-Pet™ is one of the first cannabinoid (CBD) product designed specifically for cats and dogs. Available over-the-counter, Canna-Pet™ produces veterinarian recommended, legal, cannabidiol (CBD) products for animals, made from industrial hemp and manufactured in the USA. Canna-Pet® products contain not only CBD, but carefully controlled ratios of other cannabinoids and terpenes. Now available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). For more information visit: .
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company''s business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company''s filings with the SEC, including, the Company''s current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.
:
Peak Pharmaceuticals, Inc. Investor Relations
E:
T: +1 (800) 713-9091
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.03.2015 - 07:55 Uhr
Sprache: Deutsch
News-ID 1341408
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BOULDER, CO
Phone:
Kategorie:
Equipment & Supplies
Anmerkungen:
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peak Pharmaceuticals Updates Research and Commercial Activities for Q1
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peak Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
